TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:55
Arcturus Therapeutics Holdings Inc. ( ARCT ) https://arcturusrx.com
16.93USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-48.65%
ARCT
SPY
32.66%
-56.70%
ARCT
SPY
108.59%
ARCT
47.73%
SPY
302.52%
-35.50%
ARCT
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
418.92
211.16
0.22
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.04
2.82
1.60
-10.43
0.00
-3.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-25.76
100.00
-42.87
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
16.1328
-19.57
-21.77
3.21
Other Earnings and Cash Flow Stats:
Arcturus Therapeutics Holdings Inc. ( ARCT ) Net Income TTM ($MM) is -59.51
Arcturus Therapeutics Holdings Inc. ( ARCT ) Operating Income TTM ($MM) is -73.39
Arcturus Therapeutics Holdings Inc. ( ARCT ) Owners' Earnings Annual ($MM) is 0.00
Arcturus Therapeutics Holdings Inc. ( ARCT ) Current Price to Owners' Earnings ratio is 0.00
Arcturus Therapeutics Holdings Inc. ( ARCT ) EBITDA TTM ($MM) is -69.87
Arcturus Therapeutics Holdings Inc. ( ARCT ) EBITDA Margin is -42.87%
Capital Allocation:
Arcturus Therapeutics Holdings Inc. ( ARCT ) has paid 0.00 dividends per share and bought back -0.488 million shares in the past 12 months
Arcturus Therapeutics Holdings Inc. ( ARCT ) has reduced its debt by 21.796 million USD in the last 12 months
Capital Structure:
Arcturus Therapeutics Holdings Inc. ( ARCT ) Interest-bearing Debt ($MM) as of last quarter is 29
Arcturus Therapeutics Holdings Inc. ( ARCT ) Annual Working Capital Investments ($MM) are 9
Arcturus Therapeutics Holdings Inc. ( ARCT ) Book Value ($MM) as of last quarter is 261
Arcturus Therapeutics Holdings Inc. ( ARCT ) Debt/Capital as of last quarter is 11%
Other Balance Sheet Stats:
Arcturus Therapeutics Holdings Inc. ( ARCT ) has 237 million in cash on hand as of last quarter
Arcturus Therapeutics Holdings Inc. ( ARCT ) has 69 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Arcturus Therapeutics Holdings Inc. ( ARCT ) has 27 common shares outstanding as of last quarter
Arcturus Therapeutics Holdings Inc. ( ARCT ) has 0 million USD of preferred stock value
Academic Scores:
Arcturus Therapeutics Holdings Inc. ( ARCT ) Altman Z-Score is 1.36 as of last quarter
Arcturus Therapeutics Holdings Inc. ( ARCT ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Arcturus Therapeutics Holdings Inc. ( ARCT ) largest shareholder is owning shares at 0.00 ($MM) value
Chivukula Pad(an insider) Sold 12000 shares of Arcturus Therapeutics Holdings Inc. ( ARCT ) for the amount of $249121.20 on 2024-10-15
8.46% of Arcturus Therapeutics Holdings Inc. ( ARCT ) is held by insiders, and 95.73% is held by institutions
Arcturus Therapeutics Holdings Inc. ( ARCT ) went public on 2020-04-16
Other Arcturus Therapeutics Holdings Inc. ( ARCT ) financial metrics:
FCF:-61.97
Unlevered Free Cash Flow:0.00
EPS:-1.02
Operating Margin:-25.76
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-10.54
Beta:3.21
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Arcturus Therapeutics Holdings Inc. ( ARCT ) :
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.